Blog/News

Why We Invested in DataGrail

By Alexandre Nossovskoi | October 26, 2022

DataGrail’s approach to first deeply focus on automating data privacy resulted in a robust tech platform that we believe, in the long-term, will outcompete their closest rivals. This platform enables the company to address the burgeoning middle-market, for which competing solutions are weak, and enable it to adapt to future regulation and new opportunities more easily in data privacy and security.

Read More

Antios Therapeutics Raises $96 Million in a Series B Financing

By Sixty Degree Capital | October 21, 2021

Funding will support the Phase 2 clinical program of ATI-2173 in HBV Soleus Capital led the round with new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as Altium Capital, Amzak Health, Granite…

Read More

Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies

By Sixty Degree Capital | October 20, 2021

GAITHERSBURG, Md., April 13, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds…

Read More

Arcellx Announces Executive Appointments

By Sixty Degree Capital | October 20, 2021

Dr. Christopher Heery joins as Chief Medical Officer and Neeraj Teotia joins as Chief Commercial Officer GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new…

Read More